{"id":"NCT03585270","sponsor":"Idorsia Pharmaceuticals Ltd.","briefTitle":"Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain","officialTitle":"A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Assess the Efficacy and Safety of Clazosentan in Preventing Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI), in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-03","primaryCompletion":"2022-06-13","completion":"2022-11-18","firstPosted":"2018-07-12","resultsPosted":"2024-01-10","lastUpdate":"2024-01-10"},"enrollment":409,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Aneurysmal Subarachnoid Hemorrhage"],"interventions":[{"type":"DRUG","name":"Clazosentan","otherNames":["ACT-108475"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Clazosentan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.","primaryOutcome":{"measure":"Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation","timeFrame":"Up to 14 days post-study drug initiation","effectByArm":[{"arm":"Clazosentan","deltaMin":32,"sd":null},{"arm":"Placebo","deltaMin":35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.7338"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":3},"locations":{"siteCount":80,"countries":["United States","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Poland","Spain","Sweden"]},"refs":{"pmids":["39126720","36539711"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":207},"commonTop":["Pyrexia","Hyponatraemia","Cerebral vasoconstriction","Constipation","Hypokalaemia"]}}